Among sectors, barring media and pharma, all the sectors closed in green territory, with banking, financials, IT, and FMCG closing above 1% each

The dollar index fell by 0.02% to 92.28 against the basket of other Asian currencies, following news that US lawmakers may restart negotiations on economic stimulus

The total coronavirus cases mounted to 90,04,365 and the death toll climbed to 1,32,162 with the novel coronavirus claiming 584 lives in a span of 24 hours in the country

The European commission has sealed deals with several pharmaceutical companies including BioNTech and Pfizer to buy millions of doses of vaccines on behalf of all EU Member States

India Stock Highlights Updates Today: Bajaj Finserv followed by Tata Steel, Titan, Bajaj Finance, HDFC twins and Kotak Bank were among the top gainers on Sensex pack. On the other hand, ICICI Bank, ONGC, Axis Bank, SBI and IndusInd Bank were among the laggards

A fast and cheap coronavirus testing kit that can provide results in 40 minutes was launched in Delhi on Thursday. The indigenously developed testing kit for coronavirus based on the gene-editing technology CRISPR called Feluda was launched by Tata group in collaboration with the Apollo group of hospitals. The test is likely to be cheaper than the current gold standard RT-PCR and equally accurate, helping in scaling up COVID-19 testing. Watch the video for more.Also Read: Pfizer share rises nearly 7% after firm says COVID-19 vaccine 95% effective

Pharmaceutical industry giant Pfizer and its German partner BioNTech had stated on November 18 that their vaccine candidate was 95 per cent effective in preventing COVID-19 infections during late-stage trials

Equities also stepped back after soft US retail sales data. Economic restrictions after the closure of the public school system in New York also kept sentiments tepid today across all markets, leading to profit booking.

Late-stage trials of the Oxford vaccine are still awaited but hopes are high that it'll also join frontrunners' league with Pfizer, Moderna and Russia's Sputnik V

US pharma giants Pfizer and Moderna have released the results of clinical trials of their respective experimental coronavirus vaccines, with both reporting an efficacy of over 90 per cent. The Russian vaccine, Sputnik V has also shown encouraging results in the late-stage trials. By when will the first coronavirus vaccine be ready? Watch as the experts explain the status of the global COVID-19 vaccines, with their existing challenges.Also Read: Pfizer share rises nearly 7% after firm says COVID-19 vaccine 95% effective

Reversing the trend after 10 days of consecutive gains, YES Bank share price today opened at Rs 14.57 today and later rose to the day's high of Rs 14.69 on BSE. However, the stock also hit the day's low of Rs 14.45, falling 1.5% against the earlier close of Rs 14.68

The domestic unit opened at 74.28 per US dollar at the interbank forex market and gained ground and touched 74.23. In volatile trade, the local unit also fell by 13 paise to 74.32 per dollar over its previous close

Pfizer stock opened with a gain of 6.73% at Rs 5240 on BSE

India Stock Market Highlights Today: Infosys, HCL Tech, SBI, Airtel, HUL were among the top losers today, while Bajaj twins, Tata Steel, Titan, ONGC, M&M, NTPC were among the top gainers on Sensex pack 

Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report

Pfizer and BioNTech informed that primary efficacy analysis of their coronavirus vaccine candidate showed that it was 95 per cent effective beginning 28 days after the first dose

Why are other bidders in the race to acquire DHFL (either its retail business or the combined business) not amused with Adani Group's bid for the housing finance company?

Markets currently are witnessing strong flows from foreign portfolio investors (FPIs) with investments already surpassing the October levels

Pfizer says Phase 3 study of their COVID-19 vaccine candidate met \"all primary efficacy endpoints\".  During its early analysis, vaccine had shown 90 per cent efficacy but final analysis involving 170 confirmed cases of COVID-19 showed 95 per cent efficacy

The FDA requires manufacturers to follow at least half of the people who received vaccines in their Phase 3 clinical trials for two months, to ensure there is at least that amount of safety data before a vaccine is considered for use